Adult onset Still's disease after first cycle of pemetrexed and gemcitabine for non-small cell lung cancer

被引：11

作者：

Bosch-Barrera, Joaquim ^{[1
]}

Montero, Alberto ^{[2
]}

Maria Lopez-Picazo, Jose ^{[1
]}

Garcia-Foncillas, Jesus ^{[1
]}

Ferrer, Marta ^{[3
]}

Ramon Yuste, Jose ^{[2
]}

Gil-Bazo, Ignacio ^{[1
]}

机构：

[1] Univ Navarra Clin, Dept Oncol, Pamplona 31008, Spain

[2] Univ Navarra Clin, Div Infect Dis, Pamplona 31008, Spain

[3] Univ Navarra Clin, Dept Allergy & Clin Immunol, Pamplona 31008, Spain

来源：

LUNG CANCER | 2009年 / 64卷 / 01期

关键词：

Adult onset Still's disease; Pemetrexed; Skin rash; Arthralgia; Ferritin; Lung cancer; PHASE-II TRIAL; FRONT-LINE THERAPY; 1ST-LINE TREATMENT; CHEMOTHERAPY; COMBINATION; CARBOPLATIN; LY231514;

D O I：

10.1016/j.lungcan.2008.09.013

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Pemetrexed is a multitargeted antifolate approved for the second-line treatment of locally advanced or metastatic non-small cell lung cancer. The combination of pemetrexed with gemcitabine has been studied in several clinical trials showing a promising antitumor activity with a Mild toxicity Profile. We present the case of a patient who experienced fever, arthralgia, skin rash and high serum ferritin levels after first cycle of this chemotherapy combination, compatible with an adult onset Still's disease. This adverse event has not been previously reported. (C) 2008 Elsevier Ireland Ltd. All rights reserved.

引用

页码：124 / 126

页数：3

共 20 条

[1]

CALABRO JJ, 1986, J RHEUMATOL, V13, P827

[2]

Choi JH, 2003, J RHEUMATOL, V30, P2422

[3]

Cush JJ, 2000, B RHEUM DIS, V49, P1

[4] ADULT-ONSET STILLS DISEASE - CLINICAL COURSE AND OUTCOME [J].

CUSH, JJ ;

MEDSGER, TA ;

CHRISTY, WC ;

HERBERT, DC ;

COOPERSTEIN, LA .

ARTHRITIS AND RHEUMATISM, 1987, 30 (02) :186-194

[5] Diagnosis and management of adult onset Still's disease [J].

Efthimiou, P ;

Paik, PK ;

Bielory, L .

ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 (05) :564-572

[6]

Fautrel B, 2001, J RHEUMATOL, V28, P322

[7] Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy [J].

Hanna, N ;

Shepherd, FA ;

Fossella, FV ;

Pereira, JR ;

De Marinis, F ;

von Pawel, J ;

Gatzemeier, U ;

Tsao, TCY ;

Pless, M ;

Muller, T ;

Lim, HL ;

Desch, C ;

Szondy, K ;

Gervais, R ;

Shaharyar ;

Manegold, C ;

Paul, S ;

Paoletti, P ;

Einhorn, L ;

Bunn, PA .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (09) :1589-1597

[8] Severe systemic inflammatory response syndrome with shock and ARDS resulting from Still's disease - Clinical response with high-dose pulse methylprednisolone therapy [J].

Iglesias, J ;

Sathiraju, S ;

Marik, PE .

CHEST, 1999, 115 (06) :1738-1740

[9] Pemetrexed-associated urticarial vasculitis [J].

Lopes, G ;

Vincek, V ;

Raez, LE .

LUNG CANCER, 2006, 51 (02) :247-249

[10] Randomized phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small-cell lung cancer [J].

Ma, CX ;

Nair, S ;

Thomas, S ;

Mandrekar, SJ ;

Nikcevich, DA ;

Rowland, KM ;

Fitch, TR ;

Windschitl, HE ;

Hillman, SL ;

Schild, SE ;

Jett, JR ;

Obasaju, C ;

Adjei, AA .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) :5929-5937

← 1 2 →